Key Events This Week
3 Aug: Stock opens at ₹806.10, up 1.14% on strong volume
4 Aug: Q1 FY27 results reveal strong revenue growth amid margin concerns
6 Aug: Valuation upgrade signals renewed price attractiveness; stock hits weekly high ₹834.60 (+2.27%)
7 Aug: Technical momentum shifts amid mixed signals; stock closes at ₹829.65 (-0.59%)
3 August: Positive Start with 1.14% Gain
Alembic Pharmaceuticals began the week on a strong footing, closing at ₹806.10, up ₹9.05 or 1.14% from the previous Friday’s close of ₹797.05. This outpaced the Sensex’s 0.82% gain to 36,985.17. The volume was moderate at 4,177 shares, signalling early investor interest. The positive momentum set the tone for the week, supported by anticipation around the company’s upcoming quarterly results.
4 August: Q1 FY27 Results Highlight Revenue Growth but Margin Volatility
On 4 August, Alembic Pharmaceuticals reported its Q1 FY27 results, showcasing strong revenue growth that masked concerns over margin volatility. The stock responded positively, rising 0.43% to ₹809.60 despite the Sensex slipping 0.14% to 36,933.47. The results underscored the company’s ability to expand top-line performance, though investors remained cautious about fluctuating profitability metrics. Volume surged to 19,917 shares, reflecting heightened trading activity amid the earnings announcement.
6 August: Valuation Upgrade Spurs 2.27% Rally to Weekly High
Alembic Pharmaceuticals attracted renewed attention on 6 August following a valuation upgrade from very attractive to attractive, signalling improved price appeal despite a recent downgrade in its overall Mojo Grade to Sell. The stock surged 2.27% to a weekly high of ₹834.60, outperforming the Sensex’s 0.28% gain to 37,177.57. Trading volume remained robust at 48,856 shares. Key valuation metrics such as a P/E ratio of 21.31 and EV/EBITDA of 14.77 positioned Alembic favourably against more expensive peers like Gland Pharma and Emcure Pharma, which trade at P/E multiples near 40 or higher. This shift suggested a more compelling entry point for value-oriented investors despite ongoing concerns about earnings quality and growth prospects.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
7 August: Technical Momentum Shifts Amid Mixed Market Signals
Despite a slight decline of 0.59% to ₹829.65 on 7 August, Alembic Pharmaceuticals demonstrated a notable shift in technical momentum from mildly bearish to sideways. The stock traded between ₹816.55 and ₹836.70 during the session, closing below the previous day’s high but maintaining gains for the week. Technical indicators presented a complex picture: weekly MACD and KST oscillators were bullish, signalling short-term momentum, while monthly indicators remained bearish, reflecting longer-term caution. The Relative Strength Index (RSI) showed neutral readings, consistent with consolidation. On-balance volume (OBV) was bullish on both weekly and monthly charts, suggesting accumulation despite mixed price action. The Sensex declined 0.21% to 37,099.57 on the same day, underscoring Alembic’s relative resilience.
Alembic Pharmaceuticals Ltd. or something better? Our SwitchER feature analyzes this small-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Daily Price Comparison: Alembic Pharmaceuticals vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-08-03 | Rs.806.10 | +1.14% | 36,985.17 | +0.82% |
| 2026-08-04 | Rs.809.60 | +0.43% | 36,933.47 | -0.14% |
| 2026-08-05 | Rs.816.10 | +0.80% | 37,074.66 | +0.38% |
| 2026-08-06 | Rs.834.60 | +2.27% | 37,177.57 | +0.28% |
| 2026-08-07 | Rs.829.65 | -0.59% | 37,099.57 | -0.21% |
Key Takeaways
Positive Signals: Alembic Pharmaceuticals outperformed the Sensex with a 4.09% weekly gain versus 1.13%, driven by strong revenue growth in Q1 FY27 and a valuation upgrade that highlighted its relative price attractiveness. The stock’s P/E ratio of 21.31 and EV/EBITDA of 14.77 remain significantly lower than many peers, offering a potentially compelling entry point. Technical indicators on weekly charts suggest emerging bullish momentum, supported by positive volume trends.
Cautionary Notes: Despite valuation improvements, the overall Mojo Grade remains a Sell, reflecting concerns over earnings quality, margin volatility, and growth prospects. The technical momentum is mixed, with monthly indicators still bearish and daily moving averages mildly negative. The stock’s small-cap status adds volatility risk, and recent price action remains below the 52-week high of ₹1,004.95, indicating resistance at higher levels.
Conclusion
Alembic Pharmaceuticals Ltd. demonstrated a resilient and positive weekly performance, supported by strong quarterly revenue growth and a more attractive valuation profile relative to its sector peers. The stock’s technical momentum is evolving, with short-term bullish signals tempered by longer-term caution. While the valuation upgrade signals renewed investor interest, the overall Sell grade and mixed technical indicators counsel a balanced approach. Investors should monitor upcoming earnings updates and technical developments closely to assess whether the current consolidation phase will lead to a sustained breakout or further volatility within this small-cap pharmaceutical stock.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
